# Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

> **NCT06954480** · PHASE2 · RECRUITING · sponsor: **Queen Mary University of London** · enrollment: 140 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Datopotamab Deruxtecan (Dato-DXd)
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT06954480
- **Lead sponsor:** Queen Mary University of London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-27
- **Primary completion:** 2028-02
- **Final completion:** 2030-02
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2025-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06954480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06954480, "Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06954480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*